Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel
OTCMKTS:SKVI

Skinvisible Q2 2024 Earnings Report

$0.21 0.00 (0.00%)
As of 06/26/2026
ProfileEarnings History

Skinvisible EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Skinvisible Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skinvisible Announcement Details

Quarter
Q2 2024
Date
8/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Skinvisible Earnings Headlines

SKINVISIBLE INC by Skinvisible, Inc. Insider Trading Activity | OTC:SKVI | Benzinga
May 17, 2026  |  benzinga.comhttps://www.benzinga.com/quote/SKVI/insider-trades
Skinvisible Inc.
May 11, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/SKVI/financials
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
June 28 at 1:00 AM  |  Porter & Company (Ad)
Skinvisible Stock Price History
October 9, 2025  |  investing.comhttps://www.investing.com/equities/skinvisible-inc-historical-data
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments ...
September 19, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OVATF/pressreleases/34883721/ovation-science-and-skinvisible-pharmaceuticals-enhance-their-strategic-partnership-in-the-obesity-market-with-innovative-cannabinoid-delivery-technology-with-new-developments-and-patent-protection/
Skinvisible Delays 10-K Filing Due to Compilation Issues
March 31, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/skinvisible-delays-10-k-filing-due-to-compilation-issues?utm_source=marketbeat.com&utm_medium=referral
See More Skinvisible Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skinvisible? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skinvisible and other key companies, straight to your email.

About Skinvisible

Skinvisible (OTCMKTS:SKVI), Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

View Skinvisible Profile
Earnings Tools